Our previous report demonstrated that using FRAX597 (PAK1 inhibitor) with gemcitabine produced the maximal inhibitory effect on tumour growth in an immunocompetent (C57BL/6) murine orthotopic pancreatic cancer model [21]. This evidence concerns the gene PAK1 and pancreatic neoplasm.